Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine

Author's Department

Biology Department

Third Author's Department

Biotechnology Program

Fourth Author's Department

Biotechnology Program

Fifth Author's Department

Chemistry Department

Find in your Library

https://doi.org/10.3390/pharmaceutics16020241

All Authors

Roua A. Nouh, Ahmed Kamal, Oluwaseyi Oyewole, Walaa A. Abbas, Bishoy Abib, Abdelrouf Omar, Somaia T. Mansour, Anwar Abdelnaser

Document Type

Research Article

Publication Title

Pharmaceutics

Publication Date

2-1-2024

doi

10.3390/pharmaceutics16020241

Abstract

Multiple sclerosis is the predominant autoimmune disorder affecting the central nervous system in adolescents and adults. Specific treatments are categorized as disease-modifying, whereas others are symptomatic treatments to alleviate painful symptoms. Currently, no singular conventional therapy is universally effective for all patients across all stages of the illness. Nevertheless, cannabinoids exhibit significant promise in their capacity for neuroprotection, anti-inflammation, and immunosuppression. This review will examine the traditional treatment for multiple sclerosis, the increasing interest in using cannabis as a treatment method, its role in protecting the nervous system and regulating the immune system, commercially available therapeutic cannabinoids, and the emerging use of cannabis in nanomedicine. In conclusion, cannabinoids exhibit potential as a disease-modifying treatment rather than merely symptomatic relief. However, further research is necessary to unveil their role and establish the safety and advancements in nano-cannabinoid medicine, offering the potential for reduced toxicity and fewer adverse effects, thereby maximizing the benefits of cannabinoids.

Comments

Review. Record derived from SCOPUS.

Link to Full Text
Find this item online

Share

COinS